Literature DB >> 3410538

Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.

A Fattom1, W F Vann, S C Szu, A Sutton, X Li, D Bryla, G Schiffman, J B Robbins, R Schneerson.   

Abstract

A scheme for the synthesis and purification of conjugates, composed of the type 12F capsular polysaccharide of Streptococcus pneumoniae (Pn12F) and diphtheria toxoid, is described. The scheme is a modification of that described previously for the Vi capsular polysaccharide of Salmonella typhi, a linear homopolymer of N-acetylgalactoseaminouronic acid (S. C. Szu, A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins, J. Exp. Med. 166:1510-1524, 1986). Pn12F is a branched-chain copolymer composed of a hexasaccharide repeating unit containing an aminouronic acid, N-acetylmannoseaminouronic acid (K. Leontein, B. Lindberg, and J. Lonngren, Can. J. Chem. 59:2081-2085, 1981). Sulfhydryl groups were introduced into Pn12F by forming an amide bond between cystamine and carboxyl groups of N-acetylmannoseaminouronic acid in the presence of a carbodiimide. The disulfide moiety of cystamine was reduced to form the cysteamine derivative of Pn12F which was, in turn, covalently bound to diphtheria toxoid by using the heterobifunctional linker N-succinimidyl-3-(2-pyridylthio)propionate. Unbound, high-molecular-weight Pn12F was removed from the conjugate by hydrophobic interaction chromatography through octyl Sepharose by using n-octyl-beta-D-glucopyranoside as the eluent. In young outbred mice, Pn12F did not elicit detectable serum antibodies. Pn12F-diphtheria toxoid, in contrast, elicited antibodies after two injections and had T-cell-dependent properties as evidenced by a response to priming and by its ability to elicit booster responses. This scheme seems applicable to the synthesis of conjugates with other capsular polysaccharides containing aminouronic acids. Clinical evaluation of Pn12F-diphtheria toxoid conjugates in healthy and in immunocompromised hosts is planned.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410538      PMCID: PMC259563          DOI: 10.1128/iai.56.9.2292-2298.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

Review 2.  Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future.

Authors:  J B Robbins
Journal:  Immunochemistry       Date:  1978-11

3.  Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium.

Authors:  S B Svenson; M Nurminen; A A Lindberg
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

4.  A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques.

Authors:  G Schiffman; R M Douglas; M J Bonner; M Robbins; R Austrian
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

5.  Pneumococcal infections after human bone-marrow transplantation.

Authors:  D J Winston; G Schiffman; D C Wang; S A Feig; C H Lin; E L Marso; W G Ho; L S Young; R P Gale
Journal:  Ann Intern Med       Date:  1979-12       Impact factor: 25.391

6.  Surface polysaccharide from Staphylococcus aureus M that contains taurine, D-aminogalacturonic acid, and D-fucosamine.

Authors:  D F Liau; M A Melly; J H Hash
Journal:  J Bacteriol       Date:  1974-09       Impact factor: 3.490

7.  Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent.

Authors:  J Carlsson; H Drevin; R Axén
Journal:  Biochem J       Date:  1978-09-01       Impact factor: 3.857

8.  Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine.

Authors:  C V Broome; R R Facklam; D W Fraser
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245

9.  Spatial requirements between haptenic and carrier determinants for T-dependent antibody responses.

Authors:  S Fong; D E Nitecki; R M Cook; J W Goodman
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  17 in total

1.  Surface organization and nanopatterning of collagen by dip-pen nanolithography.

Authors:  D L Wilson; R Martin; S Hong; M Cronin-Golomb; C A Mirkin; D L Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

5.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

6.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 8.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

9.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

10.  Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.

Authors:  A Fattom; C Lue; S C Szu; J Mestecky; G Schiffman; D Bryla; W F Vann; D Watson; L M Kimzey; J B Robbins
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.